ESTIMATED
05/14/2024
05/14/2024
(AS OF MARCH 31)
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 0 | -$1.18 | -$1.18 | -$1.18 |
Q2 2024 | 1 | -$1.05 | -$1.05 | -$1.05 |
Q3 2024 | 0 | -$0.96 | -$0.96 | -$0.96 |
Q4 2024 | 0 | -$0.87 | -$0.87 | -$0.87 |
Q1 2025 | 0 | -$0.85 | -$0.85 | -$0.85 |
Q2 2025 | 0 | -$0.78 | -$0.78 | -$0.78 |
Q3 2025 | 0 | -$0.74 | -$0.74 | -$0.74 |
Q4 2025 | 0 | -$0.65 | -$0.65 | -$0.65 |
Vivos Therapeutics, Inc. last posted its earnings results on Tuesday, May 14th, 2024. The company reported $-1.63 earnings per share for the quarter, missing analysts' consensus estimates of $-1.17 by $0.46. The company had revenue of 3.42 M for the quarter and had revenue of 13.80 M for the year. Vivos Therapeutics, Inc. has generated $-11 earnings per share over the last year ($-11.14 diluted earnings per share) and currently has a price-to-earnings ratio of -0.35. Vivos Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 14th, 2024 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 05/14/2024 | Q1 2024 | -$1.17 | -$1.63 | -0.46 | $3.41 M | $3.42 M | 03/28/2024 | Q4 2023 | -$1.90 | -$2.32 | -0.42 | $3.41 M | $3.25 M | 09/29/2023 | Q3 2023 | -$1.75 | $3.30 M | 08/16/2023 | Q2 2023 | -$3.75 | -$4.62 | -0.87 | $3.40 M | 06/08/2023 | Q1 2023 | $4.82 | $4.01 M | $3.86 M | 03/30/2023 | Q4 2022 | -$5.50 | -$7.93 | -2.43 | $4.55 M | $3.95 M | 12/20/2022 | Q3 2022 | -$0.28 | -$6.43 | -6.15 | $4.25 M | 12/20/2022 | Q2 2022 | -$0.28 | -$8.27 | -7.99 | $4.18 M | 05/16/2022 | Q1 2022 | -$7.25 | -$4.95 | 2.3 | $3.46 M | 03/31/2022 | Q4 2021 | -$8.02 | $4.85 M | $4.39 M | 11/15/2021 | Q3 2021 | -$4.00 | -$6.55 | -2.55 | $4.50 M | $4.55 M | 08/12/2021 | Q2 2021 | -$4.00 | -$4.87 | -0.87 | $3.60 M | $4.50 M | 05/17/2021 | Q1 2021 | -$4.25 | -$4.67 | -0.42 | $3.45 M | 03/25/2021 | Q4 2020 | -$20.70 | $3.21 M | $3.31 M | 09/29/2020 | Q3 2020 | -$4.13 | $3.29 M | 06/29/2020 | Q2 2020 | -$3.33 | $3.27 M | 03/31/2020 | Q1 2020 | -$5.67 | $3.20 M | 12/30/2019 | Q4 2019 | -$5.79 | $3.06 M | 09/29/2019 | Q3 2019 | -$6.74 | $3.32 M |
---|
A. Vivos Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 14th, 2024 based off last year's report dates.
A. The conference call for Vivos Therapeutics, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for Vivos Therapeutics, Inc.'s latest earnings report can be read online.
A. Vivos Therapeutics, Inc. (NASDAQ:VVOS) has a recorded annual revenue of $13.80 M.
A. Vivos Therapeutics, Inc. (NASDAQ:VVOS) has a recorded net income of $13.80 M. Vivos Therapeutics, Inc. has generated $-11.14 earnings per share over the last four quarters.
A. Vivos Therapeutics, Inc. (NASDAQ:VVOS) has a price-to-earnings ratio of -0.35 and price/earnings-to-growth ratio is -0.06.